AFT Pharmaceuticals Limited Overview
Pro stress-test →AFT Pharmaceuticals develops, markets, and distributes pharmaceutical products across allergy, cold and flu, digestive health, eye care, first aid, pain management, skin care, and hospital applications in New Zealand, Australia, Asia, and internationally. The company has set a goal of achieving NZ$300 million in revenue by the end of 2027.
Strategic Profile
Pro stress-test →AFT has an R&D collaboration with Belgium's Hyloris Pharmaceuticals to develop a novel innovative injectable iron deficiency therapy. The company's product line extends to over 130 prescription and non-prescription products in Australasia with offices in Singapore, Kuala Lumpur, Sydney and Auckland. AFT exports or licenses products to over 109 countries.
Competitive Landscape
Pro stress-test →AFT competes in the generic and branded pharmaceuticals sector against both multinational companies and regional players. Key competitive advantages include proprietary formulations (particularly Maxigesic combination products), established distribution networks across Australasia, and a robust pipeline of innovative injectable therapies developed through strategic partnerships.
Industry Context
AFT Pharmaceuticals Limited operates in Pharmaceutical Manufacturing and Distribution.
Key facts
Founded: 1997 · Headquarters: Auckland, New Zealand · Revenue: NZ$300M target (FY2027)